P-0244 - Single institution results of first- line treatment with bevacizumab plus chemotherapy in metastatic colorectal cancer (mCRC)

Date 28 June 2014
Event World GI 2014
Session Poster Session
Topics Anti-Cancer Agents & Biologic Therapy
Colon Cancer
Rectal Cancer
Presenter Jaroslava Barkmanova
Citation Annals of Oncology (2014) 25 (suppl_2): ii14-ii104. 10.1093/annonc/mdu165
Authors J. Barkmanova1, L. Petruzelka2, E. Sedlackova2, M. Vocka2, K. Hejduk3, Z. Bortlicek3
  • 1Dept.of Oncology, 1st Faculty of Medicine and General Faculty Hospital, Prague/CZ
  • 2Dept. of Oncology, 1st Faculty of Medicine and General Faculty Hospital Prague, Prague /CZ
  • 3Institute of Biostatistics and Analysis, Masaryk University Brno, Brno/CZ

Abstract

Introduction

We reviewed the outcomes of metastatic colorectal cancer patients referred to the Department of Oncology, First Faculty of Medicine Charles University in Prague over a 5 year period (2005 to 2010) based on registry administered by the Institute of Biostatistics and Analysis (IBA) in unselected population treated with combined chemotherapy plus bevacizumab. In this period 2005 – 2010 bevacizumab was the only monoclonal antibody registered in the Czech Republic for the treatment of mCRC.

Methods

Data of 122 patients was collected from hospital records, including demographic, treatment and outcome. The retrospective analysis of the treatment of our patients was done with respect to the type of first-line chemotherapy, adverse events (AE), tumour response, progression –free survival (PFS) and overall survival (OS).

Results

Patients were 58% (n = 71) male and 42% (n = 51) female, mean age 62 [range 22-78] years. All patients received bevacizumab, 75,4% in combination with FOLFOX4, 13,9% with FOLFIRI and 10,7% with other regimens. Median duration of first line treatment was 7,6 months (1,4 – 19,8 months). Analysis according KRAS status will be presented. CR was reached in 13,9%, PR in 40,2%, SD in 33,6%, PD in 6,6% and not assessed in 5,7%. The most frequent AE were hypertension 7,4%, proteinuria 4,1%, thromboembolic events 3,3% and bleeding 0,8%. Median PFS was 9,0 months (7,6-10,4). Median OS was 24,7 months (18,6-30,7).

Conclusion

The outcomes of patients in this retrospective cohort study are in range of the outcomes of patients in highly selective clinical trials. The analysis of the impact of clinical and biological biomarkers on survival of patients treated with chemotherapy plus bevacizumab is ongoing. Supported by PRVOUK-P-27/LF1/1 and MPO TIP FR-TI3/666.